Objective: Newborn screening for biotinidase deficiency can be performed using a fluorometric enzyme assay on dried blood spot specimens. As a pre-requisite to the consolidation of different enzymatic assays onto a single platform, we describe here a novel analytical method for detecting biotinidase deficiency using the same digital microfluidic cartridge that has already been demonstrated to screen for five lysosomal storage diseases (Pompe, Fabry, Gaucher, Hurler and Hunter) in a multiplex format.
Methods: A novel assay to quantify biotinidase concentration in dried blood spots (DBS) was developed and optimized on the digital microfluidic platform using proficiency testing samples from the Centers for Disease Control and Prevention. The enzymatic assay uses 4-methylumbelliferyl biotin as the fluorogenic substrate. Biotinidase deficiency assays were performed on normal (n=200) and deficient (n=7) newborn DBS specimens.
Results: Enzymatic activity analysis of biotinidase deficiency revealed distinct separation between normal and affected DBS specimens using digital microfluidics and these results matched the expected activity.
Conclusions: This study has demonstrated performance of biotinidase deficiency assays by measurement of 4-methylumbelliferyl product on a digital microfluidic platform. Due to the inherent ease in multiplexing on such a platform, consolidation of other fluorometric assays onto a single cartridge may be realized.
Keywords: 4-MU-biotin; 4-Methylumbelliferyl biotin; Biotinidase deficiency; CDC; Centers for Disease Control and Prevention; DBS; DL-dithiothreitol; DMF; DTT; Digital microfluidic; Digital microfluidics; Dried blood spot; Dried blood spots; LSD; Lysosomal storage diseases; Multiplex assay; NBS; NCSLPH; Newborn bloodspot screening; Newborn screening; North Carolina State Laboratory of Public Health; PT; Proficiency testing.
© 2013.